
Carol M. Koslow
Examiner (ID: 12920, Phone: (571)272-1371 , Office: P/1734 )
| Most Active Art Unit | 1734 |
| Art Unit(s) | 1734, 1754, 1793, 1755, 1108 |
| Total Applications | 5011 |
| Issued Applications | 4022 |
| Pending Applications | 258 |
| Abandoned Applications | 784 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17748222
[patent_doc_number] => 20220226425
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-21
[patent_title] => METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS
[patent_app_type] => utility
[patent_app_number] => 17/712752
[patent_app_country] => US
[patent_app_date] => 2022-04-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15613
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 14
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17712752
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/712752 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | Apr 3, 2022 | Pending |
Array
(
[id] => 19217822
[patent_doc_number] => 20240182526
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-06
[patent_title] => COMPOSITIONS AND METHODS FOR MODULTING INFLAMMATORY AND DEGENERATIVE DISORDER
[patent_app_type] => utility
[patent_app_number] => 18/285227
[patent_app_country] => US
[patent_app_date] => 2022-03-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 32574
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18285227
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/285227 | COMPOSITIONS AND METHODS FOR MODULTING INFLAMMATORY AND DEGENERATIVE DISORDER | Mar 29, 2022 | Pending |
Array
(
[id] => 19744015
[patent_doc_number] => 20250032580
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-01-30
[patent_title] => USE OF ADNF POLYPEPTIDES IN THERAPY
[patent_app_type] => utility
[patent_app_number] => 18/552263
[patent_app_country] => US
[patent_app_date] => 2022-03-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34555
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18552263
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/552263 | USE OF ADNF POLYPEPTIDES IN THERAPY | Mar 24, 2022 | Pending |
Array
(
[id] => 17897106
[patent_doc_number] => 20220306768
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-29
[patent_title] => REDIRECTING DEATH-INDUCING SIGNAL COMPLEX (DISC) BY MODIFYING DEATH RECEPTOR AGONIST TO INDUCE CELL DEATH FOR CANCER TREATMENT
[patent_app_type] => utility
[patent_app_number] => 17/703523
[patent_app_country] => US
[patent_app_date] => 2022-03-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4728
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17703523
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/703523 | REDIRECTING DEATH-INDUCING SIGNAL COMPLEX (DISC) BY MODIFYING DEATH RECEPTOR AGONIST TO INDUCE CELL DEATH FOR CANCER TREATMENT | Mar 23, 2022 | Abandoned |
Array
(
[id] => 17881249
[patent_doc_number] => 20220296726
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-22
[patent_title] => BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TREM2
[patent_app_type] => utility
[patent_app_number] => 17/698185
[patent_app_country] => US
[patent_app_date] => 2022-03-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11151
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 51
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17698185
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/698185 | Bicyclic peptide ligands specific for TREM2 | Mar 17, 2022 | Issued |
Array
(
[id] => 17850429
[patent_doc_number] => 20220280470
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-08
[patent_title] => TREATMENT FOR TUMORS DRIVEN BY METABOLIC DYSFUCTION
[patent_app_type] => utility
[patent_app_number] => 17/693478
[patent_app_country] => US
[patent_app_date] => 2022-03-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 37285
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17693478
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/693478 | TREATMENT FOR TUMORS DRIVEN BY METABOLIC DYSFUCTION | Mar 13, 2022 | Pending |
Array
(
[id] => 17687690
[patent_doc_number] => 20220194982
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-23
[patent_title] => PEPTIDES AND PEPTIDE CONJUGATES FOR TREATING MENTAL DISORDERS
[patent_app_type] => utility
[patent_app_number] => 17/686748
[patent_app_country] => US
[patent_app_date] => 2022-03-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19551
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17686748
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/686748 | PEPTIDES AND PEPTIDE CONJUGATES FOR TREATING MENTAL DISORDERS | Mar 3, 2022 | Abandoned |
Array
(
[id] => 19769983
[patent_doc_number] => 20250051409
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-02-13
[patent_title] => MODULATORS OF PHOSPHATIDYLSERlNE DECARBOXYLASE AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/548600
[patent_app_country] => US
[patent_app_date] => 2022-03-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21549
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18548600
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/548600 | MODULATORS OF PHOSPHATIDYLSERlNE DECARBOXYLASE AND USE THEREOF | Mar 1, 2022 | Pending |
Array
(
[id] => 19187777
[patent_doc_number] => 20240166690
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-23
[patent_title] => MULTI-TARGET CYCLOPEPTIDE MOLECULE FOR OPIOID/NEUROPEPTIDE FF RECEPTORS, AND PREPARATION THEREFOR AND APPLICATION THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/550207
[patent_app_country] => US
[patent_app_date] => 2022-02-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11806
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18550207
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/550207 | MULTI-TARGET CYCLOPEPTIDE MOLECULE FOR OPIOID/NEUROPEPTIDE FF RECEPTORS, AND PREPARATION THEREFOR AND APPLICATION THEREOF | Feb 21, 2022 | Pending |
Array
(
[id] => 19065539
[patent_doc_number] => 20240099965
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-28
[patent_title] => OXYTOCIN READY TO INFUSE DOSAGE FORM
[patent_app_type] => utility
[patent_app_number] => 18/264067
[patent_app_country] => US
[patent_app_date] => 2022-02-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11963
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18264067
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/264067 | OXYTOCIN READY TO INFUSE DOSAGE FORM | Feb 2, 2022 | Pending |
Array
(
[id] => 19430810
[patent_doc_number] => 20240299308
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-12
[patent_title] => DRUG LOADED CAVITATION AGENT
[patent_app_type] => utility
[patent_app_number] => 18/272113
[patent_app_country] => US
[patent_app_date] => 2022-01-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17508
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 27
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18272113
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/272113 | DRUG LOADED CAVITATION AGENT | Jan 30, 2022 | Pending |
Array
(
[id] => 17593559
[patent_doc_number] => 20220143132
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-12
[patent_title] => METHOD OF TREATING PATIENTS WITH HEPATORENAL SYNDROME TYPE 1
[patent_app_type] => utility
[patent_app_number] => 17/587442
[patent_app_country] => US
[patent_app_date] => 2022-01-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9559
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 47
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17587442
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/587442 | METHOD OF TREATING PATIENTS WITH HEPATORENAL SYNDROME TYPE 1 | Jan 27, 2022 | Pending |
Array
(
[id] => 17609647
[patent_doc_number] => 20220151926
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-19
[patent_title] => LIPOSOMES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/586807
[patent_app_country] => US
[patent_app_date] => 2022-01-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16513
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 125
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17586807
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/586807 | Liposomes and uses thereof | Jan 27, 2022 | Issued |
Array
(
[id] => 17609882
[patent_doc_number] => 20220152161
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-19
[patent_title] => Blood Plasma Fractions as a Treatment for Aging-Associated Cognitive Disorders
[patent_app_type] => utility
[patent_app_number] => 17/582974
[patent_app_country] => US
[patent_app_date] => 2022-01-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19568
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 25
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17582974
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/582974 | Blood Plasma Fractions as a Treatment for Aging-Associated Cognitive Disorders | Jan 23, 2022 | Pending |
Array
(
[id] => 19172492
[patent_doc_number] => 20240158466
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-16
[patent_title] => PEGYLATED P-SELECTIN INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 18/272092
[patent_app_country] => US
[patent_app_date] => 2022-01-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 38449
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -34
[patent_words_short_claim] => 27
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18272092
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/272092 | PEGYLATED P-SELECTIN INHIBITORS | Jan 12, 2022 | Pending |
Array
(
[id] => 19431068
[patent_doc_number] => 20240299566
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-12
[patent_title] => POLY-ARGININE DERIVATIVES FOR ENHANCING BRAIN-DERIVED GROWTH FACTOR TO MITIGATE NEUROLOGICAL DISORDERS
[patent_app_type] => utility
[patent_app_number] => 18/260440
[patent_app_country] => US
[patent_app_date] => 2022-01-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11042
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18260440
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/260440 | POLY-ARGININE DERIVATIVES FOR ENHANCING BRAIN-DERIVED GROWTH FACTOR TO MITIGATE NEUROLOGICAL DISORDERS | Jan 4, 2022 | Pending |
Array
(
[id] => 19034128
[patent_doc_number] => 20240083943
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-14
[patent_title] => VEGF-REGULATING PEPTIDES
[patent_app_type] => utility
[patent_app_number] => 18/259752
[patent_app_country] => US
[patent_app_date] => 2021-12-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20999
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 16
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18259752
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/259752 | VEGF-REGULATING PEPTIDES | Dec 28, 2021 | Pending |
Array
(
[id] => 19020140
[patent_doc_number] => 20240076311
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-07
[patent_title] => METHOD FOR SYNTHESIZING PEPTIDE THIOESTERS AND HEAD-TO-TAIL AMIDE CYCLIC PEPTIDE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/259476
[patent_app_country] => US
[patent_app_date] => 2021-12-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5875
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 211
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18259476
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/259476 | METHOD FOR SYNTHESIZING PEPTIDE THIOESTERS AND HEAD-TO-TAIL AMIDE CYCLIC PEPTIDE THEREOF | Dec 26, 2021 | Pending |
Array
(
[id] => 19003615
[patent_doc_number] => 20240067686
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-02-29
[patent_title] => NOVEL PEPTIDE CAPABLE OF INHIBITING TGF-ss SIGNALING AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/269255
[patent_app_country] => US
[patent_app_date] => 2021-12-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7550
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18269255
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/269255 | NOVEL PEPTIDE CAPABLE OF INHIBITING TGF-ss SIGNALING AND USE THEREOF | Dec 21, 2021 | Pending |
Array
(
[id] => 19579876
[patent_doc_number] => 12145972
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-11-19
[patent_title] => Neuregulin-4 compounds and methods of use
[patent_app_type] => utility
[patent_app_number] => 17/559430
[patent_app_country] => US
[patent_app_date] => 2021-12-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12967
[patent_no_of_claims] => 29
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 79
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17559430
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/559430 | Neuregulin-4 compounds and methods of use | Dec 21, 2021 | Issued |